Helocyte, a portfolio company of Fortress Biotech, is focused on developing and commercializing immunotherapies for the prevention and treatment of cytomegalovirus (CMV). The company aims to secure rights to new technologies via acquisition, licensing, co-development, and other partnering, fund research and development of new technologies, and ultimately introduce new technologies to the market. Helocyte is currently progressing three immunotherapies, including PepVax and Triplex vaccines, for the treatment of cancer and infectious diseases like CMV. The company has opened Phase 2 studies of PepVax and Triplex in allogeneic hematopoietic stem cell transplant (HSCT) recipients and plans to study Triplex in recipients of allogeneic Solid Organ Transplantation. Helocyte's third program, Pentamer, is currently undergoing nonclinical development and will ultimately be studied for the prevention of congenital CMV.